Welcome to our dedicated page for Cellectis news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis stock.
Cellectis S.A. (NASDAQ: CLLS) is a clinical-stage biopharmaceutical leader developing groundbreaking allogeneic CAR-T therapies through precision gene-editing technologies. This page provides investors and industry professionals with essential updates on the company’s clinical trials, regulatory milestones, and strategic developments.
Access real-time announcements including FDA submissions, partnership agreements, and research breakthroughs. Our curated collection features press releases on TALEN®-engineered therapies, hematopoietic stem cell advancements, and financial results – all critical for evaluating this innovator in off-the-shelf cancer treatments.
Key updates cover three focus areas: clinical trial phases for UCART candidates, intellectual property developments, and collaborative research initiatives. Bookmark this page to monitor progress in scalable cancer immunotherapies and maintain informed perspectives on Cellectis’ position within the competitive gene-editing landscape.
On May 16, 2024, Cellectis released its monthly update on share capital and voting rights as stipulated by Article 223-16 of the French financial markets authority. The company, listed on Euronext Growth under the ISIN code FR0010425595, reported a total of 99,955,535 shares in its capital and 87,891,239 voting rights as of May 3, 2024. For more details, the company provided contact information for their media and investor relations teams.
In a recent press release, Cellectis provided information on their share capital and company voting rights for April 30, 2024. The total number of shares in the capital was reported as 71,955,535 with a total number of voting rights at 77,891,229. This data was disclosed in compliance with Article 223-16 of the General Regulation of the French financial markets authority.
Cellectis announced the completion of an additional equity investment of $140M by AstraZeneca. AstraZeneca purchased 10,000,000 class A convertible preferred shares and 18,000,000 class B convertible preferred shares at $5.00 per share. This move solidifies AstraZeneca's ownership in Cellectis, giving them approximately 44% of the share capital and 30% of the voting rights in the company.
Cellectis appointed Arthur Stril as the interim Chief Financial Officer, replacing Bing Wang. Mr. Stril, with a strong background in finance and business development, will oversee finance, investor relations, and business development functions. His appointment comes at a critical growth phase for Cellectis, as they advance their pipeline of assets and explore new opportunities.
Cellectis reported financial results for the fourth quarter and full year 2023, highlighting key events like clinical study updates, strategic collaborations with AstraZeneca, and cash position. The company remains focused on advancing its Phase 1 clinical trials, presenting promising data on UCART22 and UCART20x22 at the ASH conference. The collaboration with AstraZeneca aims to develop innovative cell and gene therapies. Financially, Cellectis saw a significant increase in cash position to $156 million as of December 31, 2023.
FAQ
What is the current stock price of Cellectis (CLLS)?
What is the market cap of Cellectis (CLLS)?
